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 Introduction 
 In the last few years, some evidence has been found 
for energy metabolism deﬁ ciency and mitochondrial 
DNA (mtDNA) alterations contributing to the etiopatho-
genesis of Alzheimer’s disease (AD). In 1992, Lin et al. 
 [1] identiﬁ ed, in AD patients, a G-A transition and a G-T 
transversion, both at nucleotide 5460 of mtDNA  NADH 
dehydrogenase subunit 2 gene, but these ﬁ ndings were not 
conﬁ rmed  [2] . Later, Shoffner et al.  [3] reported four poly-
morphisms (nucleotides 3196, 3397, 4336 and 956–965 
insertion), having special importance, and the tRNA 
(Gln) variant at position 4336 that modiﬁ es a moderate-
ly conserved nucleotide. Kösel et al.  [4] found in patients 
with Parkinson’s disease (PD) a known missense muta-
tion at nucleotide 3338 of the  NADH dehydrogenase sub-
unit 1  (ND1) mtDNA gene that changes the amino acid 
valine to alanine. This mutation has previously been de-
scribed by Chalmers et al.  [5] in a control subject, and it 
was absent in subsets of our PD  [6] and frontotemporal 
dementia  [7] patients.  
 We analyzed mtDNA  ND1 nucleotides 3337–3340 in 
129 AD patients and 125 healthy age-matched control 
subjects, in order to determine if mtDNA  ND1 is related 
to AD. We also tried to ﬁ nd an additional peripheral ge-
netic risk factor for the disease. 
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 Abstract 
 Alzheimer’s disease (AD) is the most common neurode-
generative disorder associated with dementia in late 
adulthood. Mitochondrial respiratory chain impairment 
has been detected in the brain, muscle, fi broblasts and 
platelets of AD patients, indicating a possible involve-
ment of mitochondrial DNA (mtDNA) in the etiology of 
the disease. Several reports have identifi ed mtDNA mu-
tations in AD patients, but there is no consensual opinion 
regarding the cause of the impairment. We have studied 
mtDNA NADH dehydrogenase subunit 1 nucleotides 
3337–3340, searching for mutations. Our study group in-
cluded 129 AD patients and 125 healthy age-matched 
controls. We have found alterations in two AD patients: 
one had two already known mtDNA modifi cations (3197 
T-C and 3338 T-C) and the other a novel transition (3199 
T-C) which, to our knowledge, has not been described 
before. 
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 Methods 
 One hundred and twenty-nine Caucasian patients (80 female 
and 49 male; mean age: 69.6  8 8.9 years, range: 41–89 years; mean 
age at onset of AD: 65.5  8 9.3 years, range: 35–86 years) with the 
diagnosis of probable AD, as deﬁ ned by standard criteria  [8, 9] and 
followed at the Neurological Unit of the University Hospital of 
Coimbra, were randomly selected for this study. The patients had 
at least 1-year history of cognitive decline conﬁ rmed by neuropsy-
chological assessment, and positive family history was reported in 
40 patients (31%). Family history was considered positive when a 
ﬁ rst degree relative had dementia. Early onset AD was considered 
when the patient started the disease course before reaching the age 
of 65 years. Global cognitive impairment was quantiﬁ ed using the 
Mini-Mental State Examination (MMSE)  [10] . The mean MMSE 
score was 12.1  8 7.9 (range 0–29) and global dementia severity was 
staged in accordance with the Clinical Dementia Rating (CDR)  [11, 
12] where CDR 0 indicates no impairment and CDR 0.5, 1, 2 and 
3 indicate questionable, mild, moderate and severe dementia, re-
spectively. Our patient group included 35 patients with CDR 1, 55 
with CDR 2 and 39 with CDR 3. One hundred and twenty-ﬁ ve 
healthy age-matched Caucasian control subjects, free of neurologi-
cal disorders (73 female and 52 male; mean age: 65.2  8 13.0 years, 
range: 37–90 years) were recruited among the staff and accompany-
ing persons of the patients. Informed consent was obtained from 
all patients and controls, according to the University Hospital Eth-
ical Council guidelines. Total cellular DNA was isolated from pe-
ripheral leukocytes (105 patients and 123 controls), cultured ﬁ bro-
 Fig. 1. Results of ﬂ uorescence-based auto-
mated sequencing analysis.  a mtDNA se-
quence of P1 surrounding the nucleo -
 tide 3197C (*).  b mtDNA sequence of P2 
surrounding the nucleotide 3199C (*).
 c mtDNA sequence of P1 surrounding the 
nucleotide 3338C (*). 
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blasts (7 patients and 1 control) and both peripheral leukocytes and 
cultured ﬁ broblasts (17 patients and 1 control) by standard proce-
dures. PCR and RFLP of patient and control DNA samples were 
performed as described previously  [6] . When a positive result was 
found, the fragments of mtDNA were sequenced as reported before 
 [7] and sequences were compared with the revised Cambridge se-
quence of the human mitochondrial genome  [13] . In order to ver-
ify if the PCR product was an ampliﬁ cation of mtDNA genes or 
nuclear pseudogenes, we also analyzed total cellular DNA isolated 
from   0  cells. DNA analyses were performed blind to the diagnosis, 
and subject identities were known only after the results had been 
completed. 
 Results and Discussion 
 Only one AD patient (P1) showed a homoplasmic 
mtDNA modiﬁ cation at nucleotides 3337–3340 by PCR-
RFLP analysis. He was 54 years old, and the onset of 
disease occurred at 53 years. Although the MMSE score 
was in the normal range (29) at the ﬁ rst visit, neuropsy-
chological assessment conﬁ rmed a deterioration in mem-
ory and language, and the patient was classiﬁ ed as mildly 
demented using CDR (1); there was no family history re-
ported. Additionally, an unexpected pattern at agarose 
gel electrophoresis occurred in another sample: fragments 
presenting lower molecular weight (141 bp + 69 bp) than 
the wild-type (210 bp + 79 bp) or mutant (289 bp) bands, 
together with the 79-bp band, were found in a 68-year-old 
male AD patient (P2) who scored 22 and 1 on the MMSE 
and CDR, respectively. His age at disease onset was 65 
years, and he had no family history. Sequence analysis 
conﬁ rmed the PCR-RFLP result. P1 presented a known 
missense transition T-C at nucleotide 3338 of the mtD-
NA  ND1 gene, which promotes the change of valine to 
alanine in the peptide chain ( ﬁ g. 1 ). This change is con-
sidered a harmless polymorphism, based on studies of 
amino acid residue substitutions  [14] , and was found 
through sequence analysis in 1 patient with hypertrophic 
cardiomyopathy  [15, 16] , 1 with PD  [4] and 1 multiple 
sclerosis control subject  [5] . This is a highly conserved 
nucleotide among the hominoid primates (data not 
shown), as well as nucleotides 3339 and 3340, which do 
not occur with nucleotide 3337. Additionally, P1 present-
ed another known T-C transition at nucleotide 3197 of 
the 16S rRNA mtDNA gene ( ﬁ g. 1 ), which had previ-
ously been described  [17] in a patient with ischemic coli-
tis and in AD, PD, AD + PD patients and Caucasian 
controls  [18] as a polymorphism, also reported as associ-
ated with the haplogroup U5, present in the European 
populations  [19] , and very weakly conserved among hom-
inoid primates (data not shown). P2 presented a normal 
sequence at nucleotides 3337–3340 (GTAC), but we have 
found a novel homoplasmic alteration at nucleotide 3199 
of the 16S rRNA mtDNA gene ( ﬁ g. 1 ), a T-C transition, 
originating a cleavage site (GTAC sequence) recognized 
by Csp 6I endonuclease and originating altogether three 
bands with 141, 79 and 69 bp, after electrophoresis. This 
is a very weakly conserved nucleotide in hominoid pri-
mates since there is a C in the genus  Pan (chimpanzee 
and bonobo), a T in  Gorilla gorilla and  Homo sapiens and 
a nucleotide deletion or a C in  Pongo pygmaeus (data not 
shown). To our knowledge, this nucleotide change is re-
ported here for the ﬁ rst time, and it seems unlikely that 
it is a causative mutation. We have screened all the other 
patients and the 125 controls for the presence of this new 
variant, but no other positive samples were found. Ad-
ditionally, there was no ampliﬁ cation of the total cellular 
DNA isolated from   0  cells, conﬁ rming that we were ana-
lyzing mtDNA and not nuclear pseudogenes. 
 Conclusion 
 mtDNA  ND1 nucleotides 3337–3340 seem unlikely to 
be a primary risk factor for AD in the population under 
study (central region of Portugal), which is in agreement 
with the current literature, but does not rule out the 
 possible contribution of  ND1 ,  16S rRNA , or any other 
mtDNA gene to the pathogenesis of AD. In fact, it is pos-
sible that distinct combinations of nonmutated electron 
transport chain components do not function identically; 
being so, nonpathogenic mtDNA variations could con-
tribute to AD risk, while at the same time explaining why 
associations between mtDNA polymorphism and AD are 
difﬁ cult to establish  [20] . 
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